Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Subviral Agents

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

Viruses with RNA Genomes

Viruses with RNA Genomes

RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...

Viral Replication: Lytic Cycle

Viral Replication: Lytic Cycle

Bacteriophages, or phages, are viruses that specifically infect bacteria. Among them, T-even bacteriophages, such as T4, exhibit a well-characterized lytic replication cycle in Escherichia coli (E. coli). This process ensures the rapid proliferation of the virus while ultimately leading to the destruction of the bacterial host.Attachment and DNA InjectionThe infection process begins with the recognition and binding of the T4 phage to the E. coli cell surface. Tail fibers of the phage...

Retroviruses

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...

Viral Mutations

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Multisite Real-World Validation of an Electronic Health Record-Integrated Generative Artificial Intelligence Tool for Venous Thromboembolism Risk Stratification.

medRxiv : the preprint server for health sciences·2026

Same author

G-PARC: Graph-Physics Aware Recurrent Convolutional neural networks for spatiotemporal dynamics on unstructured meshes.

Scientific reports·2026

Same author

HIRA-mediated H3.3 deposition preserves hepatocyte cell identity during liver aging.

Research square·2026

Same author

Targeted <sup>89</sup>Zr-Labeled metallofluorocarbon nanoemulsion for carcinoembryonic antigen PET.

Journal of nanobiotechnology·2026

Same author

Fluorine-19 MRI signal phenotype in solid tumor following in situ perfluorocarbon cell labeling.

Scientific reports·2026

Same author

Co-Expression and Co-Purification Enable Manufacturing of a Six-Monoclonal Antibody Botulinum Antitoxin Cocktail.

Toxins·2026

Search research articles

Related Experiment Video

Updated: Nov 23, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Modeling viral evolutionary dynamics after telaprevir-based treatment.

Eric L Haseltine¹, Sandra De Meyer², Inge Dierynck²

¹Vertex Pharmaceuticals Incorporated, Boston, Massachussets, United States of America.

Plos Computational Biology

|August 8, 2014

Summary

This summary is machine-generated.

A new computational model accurately quantifies hepatitis C virus (HCV) resistance dynamics after treatment failure. This model integrates qualitative and quantitative data, providing faster and more precise estimates of viral reversion to wild-type strains.

More Related Videos

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

Related Experiment Videos

Last Updated: Nov 23, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes

Published on: September 27, 2014

Area of Science:

Virology and Computational Biology
Antiviral Drug Resistance
Hepatitis C Virus (HCV) Evolution

Background:

Direct-acting antivirals like telaprevir improve sustained virologic response (SVR) in hepatitis C virus (HCV) patients.
Treatment failure with telaprevir-based regimens enriches viral populations with drug-resistant variants.
Previous resistance dynamics estimations lacked quantitative precision due to reliance on population sequence data.

Purpose of the Study:

To quantify the evolutionary dynamics of post-treatment HCV resistant variants.
To develop and qualify a computational model integrating qualitative and quantitative sequence data for resistance analysis.
To provide a framework for accurate, quantitative assessment of HCV resistance dynamics.

Main Methods:

Integrated clonal sequence analysis (5% sensitivity) with existing population sequence data (20% sensitivity).
Developed a computational model to combine qualitative and quantitative sequence data for resistance dynamics.
Qualified the model using deep-sequence data (1% sensitivity) for consistency with predictions.

Main Results:

The model predicted faster reversion to 20% resistance for HCV genotype 1a (8.3 months) compared to previous estimates (10.7 months).
For HCV genotype 1b, the model predicted rapid reversion to 20% resistance (1.0 month).
Model predictions for individual patient reversion times were comparable or faster than population sequence data estimates.
The model predicts median reversion times to 99% wild-type of 11.0 months for genotype 1a and 2.1 months for genotype 1b post-treatment failure.

Conclusions:

The developed computational model offers a robust framework for quantitative assessment of HCV resistance dynamics.
This approach improves the accuracy and speed of estimating viral reversion post-treatment.
The model facilitates better understanding of drug resistance evolution in HCV.